ZURA advances tibulizumab dual-target bispecific in autoimmune pivotal trials
ZURA is advancing a multifunctional antibody pipeline, with tibulizumab leading pivotal trials for hidradenitis suppurativa and systemic sclerosis. The bispecific targets IL-17 and BAFF for potential superior efficacy, with key data readouts expected soon.
The company is advancing a pipeline of multifunctional antibodies for autoimmune diseases, with tibulizumab in pivotal trials for hidradenitis suppurativa and systemic sclerosis. The bispecific targets both IL-17 and BAFF, with key data readouts expected.